Xiaofang Pharmaceutical: Long-term bullish on the household standing external-use medication track.

Xiaofang Pharmaceutical stated at its 2026 semi-annual results briefing that the company's future profit growth will mainly rely on two core drivers: breakthroughs in innovative drug R&D and full-channel sales expansion, while also benefiting from the long-term expansion of the external-use drug market. The company is bullish on the household standing external-use drug segment in the long term, as aging and upgraded health consumption bring stable demand and broad industry space. The company will continue to deepen its core business, advance product innovation, and seize industry opportunities.